The FDA did not fully approve sotorasib for the treatment of patients with KRAS G12C-mutated non–small cell lung cancer.
Sotorasib’s sNDA has been rejected by the FDA for the treatment of locally advanced or metastatic KRAS G12C-mutated NSCLC that has been treated with at least 1 prior line of therapy. The FDA issued a complete response letter and issued a new postmarketing requirement study to be completed no later than February 2028.1
The NDA was supported by findings from the confirmatory phase 3 CodeBreaK 200 trial. The sNDA sought full approval of sotorasib. At an ODAC meeting in October 2023, the committee found in a 10-2 vote that the primary end point of PFS per blinded independent central review could not be reliably interpreted. The ODAC concluded that the difference in PFS between the sotorasib and docetaxel arms was small, and there was no difference in overall survival (OS).
The FDA also expressed concern about the study’s integrity, as there was greater patient dropout observed in the docetaxel arm, as well as patient crossover from the docetaxel arm to the sotorasib arm prior to assessment of disease-progression.
CodeBreaK 200 is a multicenter, randomized, open-label, active-controlled, confirmatory, phase 3 study of sotorasib vs docetaxel in the ITT population. To be eligible for enrollment, patients must have received 1 or moreprevious treatments, including platinum-based chemotherapy and a checkpoint inhibitor, and have an ECOG performance status of 0 or 1.3
Overall, 345 patients were enrolled and randomly assigned in a 1:1 manner to receive oral sotorasib 960 mg (n = 171) or intravenous docetaxel 75 mg/m2 every 3 weeks (n = 174).
At a median follow-up of 17.7 months (interquartile range, 16.4-20.1), there was a 34% reduction in the risk of disease progression or death in the sotorasib arm compared with docetaxel (HR, 0.66; 95% CI, 0.51-0.86; P =.0017). This met the trial’s primary end point. The median PFS was 5.6 months (95% CI, 4.3-7.8) in the sotorasib arm vs 4.5 months (95% CI, 3.0-5.7) in the docetaxel arm. The 12-month PFS rates were 24.8% with sotorasib and 10.1% with docetaxel.4
Furthermore, the PFS benefit with sotorasib was improved independent of PD-L1 expression. No significant differences were observed in OS rates. The sotorasib arm had a 10.6-month OS (95% CI, 8.9-14.0), and the OS in the docetaxel arm was 11.3 months (95% CI, 9.0-14.9).
The safety profile of sotorasib was consistent with the known profile, and no new safety signals were identified.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More